TABLE 1.
Comparison of the clinic-laboratory data and demographic features between patients with 1) low NLR and high NLR and 2) low and high PLR.
| Characteristic | Overall (n = 314) | NLR < 2.42 (n = 159) | NLR ≥ 2.42 (n = 155) | p value | PLR < 100 (n = 157) | PLR ≥ 100 (n = 157) | p value |
|---|---|---|---|---|---|---|---|
| Gender | 0.927 | 0.034 | |||||
| Male | 270 (86.0) | 137 (86.2) | 133 (85.8) | 142 (90.5) | 128 (81.5) | ||
| Female | 44 (14.0) | 22 (13.8) | 22 (14.2) | 15 (9.5) | 29 (18.45) | ||
| Age (years) | 0.431 | 0.366 | |||||
| ≤55 | 165 (52.6) | 80 (50.3) | 85 (54.8) | 87 (55.4) | 78 (49.7) | ||
| >55 | 149 (47.4) | 79 (49.7) | 70 (45.2) | 70 (44.6) | 79 (50.3) | ||
| ECOG | 0.151 | 1.000 | |||||
| 0 | 312 (99.4) | 159 (100) | 153 (98.7) | 156 (99.4) | 156 (99.4) | ||
| 1 | 2 (0.6) | 0 (0) | 2 (1.3) | 1 (0.6) | 1 (0.6) | ||
| Etiology | 0.422 | 0.107 | |||||
| HBV | 269 (85.7) | 139 (87.4) | 130 (83.9) | 140 (89.2) | 129 (82.2) | ||
| Other | 45 (14.3) | 20 (12.6) | 25 (16.1) | 17 (10.8) | 28 (17.8) | ||
| Cirrhosis | 0.715 | 0.713 | |||||
| 218 (69.4) | 112 (70.4) | 106 (68.4) | 111 (70.7) | 107 (68.2) | |||
| Tumor size (cm) | 0.496 | 0.256 | |||||
| ≤5 | 175 (55.7) | 92 (57.9) | 83 (53.6) | 93 (59.2) | 82 (52.2) | ||
| >5 | 139 (44.3) | 67 (42.1) | 72 (46.4) | 64 (40.8) | 75 (47.8) | ||
| No. of nodules | 0.501 | 1.000 | |||||
| <3 | 160 (51.0) | 78 (49.1) | 82 (52.9) | 80 (51.0) | 80 (51.0) | ||
| ≥3 | 154 (49.0) | 81 (50.9) | 73 (47.1) | 77 (49.0) | 77 (49.0) | ||
| PVTT | 0.001 | 0.042 | |||||
| 106 (33.8) | 39 (24.5) | 67 (43.2) | 44 (28.0) | 62 (39.5) | |||
| Hepatic vein invasion | 0.116 | 0.161 | |||||
| 37 (11.8) | 14 (8.8) | 23 (14.8) | 14 (8.9) | 23 (14.7) | |||
| Child-Pugh class | 0.980 | 1.000 | |||||
| A | 310 (98.7) | 157 (98.7) | 153 (98.7) | 155 (98.7) | 155 (98.7) | ||
| B | 4 (1.3) | 2 (1.3) | 2 (1.3) | 2 (1.3) | 2 (1.3) | ||
| BCLC stage | <0.001 | 0.001 | |||||
| B | 170 (54.1) | 107 (67.3) | 63 (40.7) | 100 (63.7) | 70 (44.6) | ||
| C | 144 (45.9) | 52 (32.7) | 92 (59.3) | 57 (36.3) | 87 (55.4) | ||
| ALBI grade | 0.046 | 0.191 | |||||
| 1 | 170 (54.1) | 97 (61.0) | 73 (47.1) | 93 (59.2) | 77 (49.0) | ||
| 2 | 142 (45.2) | 61 (38.4) | 81 (52.3) | 63 (40.1) | 79 (50.3) | ||
| 3 | 2 (0.7) | 1 (0.6) | 1 (0.6) | 1 (0.7) | 1 (0.7) | ||
| Tumor distribution | 0.282 | 0.905 | |||||
| Unilobar | 210 (66.9) | 111 (69.8) | 99 (63.9) | 106 (67.5) | 104 (66.2) | ||
| Bilobar | 104 (33.1) | 48 (30.2) | 56 (36.1) | 51 (32.5) | 53 (33.8) | ||
| Extrahepatic spread (PVTT excluded) | 32 (10.2) | 8 (5.0) | 24 (15.5) | 0.003 | 10 (6.4) | 22 (14.0) | 0.039 |
| AFP (ng/dl) | 0.070 | 0.024 | |||||
| ≤200 | 167 (53.2) | 93 (58.5) | 74 (47.7) | 94 (59.9) | 73 (45.5) | ||
| >200 | 147 (46.8) | 66 (41.5) | 81 (52.3) | 63 (40.1) | 84 (54.5) | ||
| AST (U/L) | 0.003 | 0.054 | |||||
| ≤40 | 144 (45.9) | 86 (54.1) | 58 (37.4) | 81 (51.6) | 63 (40.1) | ||
| >40 | 170 (54.1) | 73 (45.9) | 97 (62.6) | 76 (48.4) | 94 (59.9) | ||
| ALT (U/L) | 0.909 | 0.087 | |||||
| ≤40 | 180 (57.3) | 92 (57.9) | 88 (56.8) | 82 (52.2) | 98 (62.4) | ||
| >40 | 134 (42.7) | 67 (42.1) | 67 (42.2) | 75 (47.7) | 59 (37.6) | ||
| Albumin (g/L) | 0.595 | 0.894 | |||||
| ≤35 | 74 (23.6) | 35 (22.0) | 39 (25.2) | 38 (24.2) | 36 (22.9) | ||
| >35 | 240 (76.4) | 124 (78.0) | 116 (74.8) | 119 (75.8) | 121 (77.1) | ||
| TBIL (umol/L) | 0.107 | 0.227 | |||||
| ≤17.1 | 242 (77.1) | 129 (81.1) | 113 (72.9) | 116 (73.9) | 126 (80.2) | ||
| >17.1 | 72 (22.9) | 30 (18.9) | 42 (27.1) | 41 (26.1) | 31 (19.8) | ||
| AST/ALT | 0.178 | 0.005 | |||||
| ≤1.18 | 156 (49.7) | 85 (53.5) | 71 (45.8) | 91 (58.0) | 65 (41.4) | ||
| >1.18 | 158 (50.3) | 74 (46.5) | 84 (54.2) | 66 (42.0) | 92 (58.6) |
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PVTT, portal vein tumor thrombus; TBIL, total bilirubin.